CO2018007096A2 - Toxina botulínica para trastornos primarios del estado de ánimo y afecto utilizando un neurotransmisor - Google Patents

Toxina botulínica para trastornos primarios del estado de ánimo y afecto utilizando un neurotransmisor

Info

Publication number
CO2018007096A2
CO2018007096A2 CONC2018/0007096A CO2018007096A CO2018007096A2 CO 2018007096 A2 CO2018007096 A2 CO 2018007096A2 CO 2018007096 A CO2018007096 A CO 2018007096A CO 2018007096 A2 CO2018007096 A2 CO 2018007096A2
Authority
CO
Colombia
Prior art keywords
disorders
neurotransmitter
botulinum toxin
primary mood
affection
Prior art date
Application number
CONC2018/0007096A
Other languages
English (en)
Inventor
Gary Borodic
Martin Acquadro
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/966,759 external-priority patent/US20160095908A1/en
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of CO2018007096A2 publication Critical patent/CO2018007096A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Resumen La invención proporciona métodos para tratar trastornos primarios del estado de ánimo y del afecto, que incluyen trastornos depresivos, ansiedad y trastornos del sueño y trastornos del SNC que comprenden la administración de una neurotoxina.
CONC2018/0007096A 2015-12-11 2018-07-06 Toxina botulínica para trastornos primarios del estado de ánimo y afecto utilizando un neurotransmisor CO2018007096A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/966,759 US20160095908A1 (en) 2005-06-14 2015-12-11 Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies
PCT/US2016/065898 WO2017100624A1 (en) 2015-12-11 2016-12-09 Botulinum toxin for primary disorders of mood and affect using neurotransmitter

Publications (1)

Publication Number Publication Date
CO2018007096A2 true CO2018007096A2 (es) 2018-11-22

Family

ID=59013649

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0007096A CO2018007096A2 (es) 2015-12-11 2018-07-06 Toxina botulínica para trastornos primarios del estado de ánimo y afecto utilizando un neurotransmisor

Country Status (13)

Country Link
EP (1) EP3386538A4 (es)
JP (1) JP2019504824A (es)
KR (1) KR20180093983A (es)
CN (1) CN109069609A (es)
AU (1) AU2016366428A1 (es)
BR (1) BR112018011663A2 (es)
CA (1) CA3007816A1 (es)
CO (1) CO2018007096A2 (es)
IL (1) IL259825A (es)
MX (1) MX2018007105A (es)
RU (1) RU2018125034A (es)
SG (1) SG11201804840SA (es)
WO (1) WO2017100624A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021137667A1 (ko) * 2019-12-30 2021-07-08 주식회사 에이티지씨 보툴리눔 신경독소를 포함하는 파킨슨병 치료용 조성물 및 이를 이용한 파킨슨병 치료 방법
CN114384185A (zh) * 2022-01-20 2022-04-22 北京航空航天大学 用于检测γ-氨基丁酸含量的试剂在制备诊断静脉流出障碍性疾病的试剂盒中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
WO2005072433A2 (en) * 2004-01-26 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Toxin induced sympathectomy
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
AU2007288226A1 (en) * 2006-08-21 2008-02-28 Prexa Pharmaceuticals, Inc. Multimediator transporter inhibitors for use in treatment of central nervous system disorders
WO2010013495A1 (ja) * 2008-07-31 2010-02-04 財団法人化学及血清療法研究所 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用
US9393291B2 (en) * 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations

Also Published As

Publication number Publication date
RU2018125034A (ru) 2020-01-13
RU2018125034A3 (es) 2020-04-15
SG11201804840SA (en) 2018-07-30
AU2016366428A1 (en) 2018-06-28
JP2019504824A (ja) 2019-02-21
CA3007816A1 (en) 2017-06-15
BR112018011663A2 (pt) 2018-12-04
CN109069609A (zh) 2018-12-21
KR20180093983A (ko) 2018-08-22
EP3386538A4 (en) 2019-07-17
MX2018007105A (es) 2018-09-07
IL259825A (en) 2018-07-31
WO2017100624A1 (en) 2017-06-15
EP3386538A1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CL2018001372A1 (es) Moléculas de anticuerpo contra april y usos de las mismas
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CO2017005034A2 (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
BR112017007902A2 (pt) composições e métodos para o tratamento de distúrbios do sistema nervoso central.
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CR20170011A (es) Compuestos de heteroarilo para la inhibición de cinasa
CR20190271A (es) Anticuerpos antitau y métodos de uso
CR20170219A (es) Inhibidores del bromodominio
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
BR112015023207A8 (pt) composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
CL2018000009A1 (es) Un proceso para tratar leche
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112016021698A2 (pt) método e aparelho para produção de fio de fibra.
BR112019011635A2 (pt) terapia genética para mucopolissacaridose, tipo i
CO2018007096A2 (es) Toxina botulínica para trastornos primarios del estado de ánimo y afecto utilizando un neurotransmisor
BR112017008097A2 (pt) método para tratar condições oculares
BR112018013928A2 (pt) composições terapêuticas e métodos para tratamento da hepatite b
BR112016015578A2 (pt) Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2
EA201700060A1 (ru) Терапевтическое средство для кератоконъюнктивальных расстройств